LBRXLB Pharmaceuticals Inc
$34.62+116% 1Y
$34.62
$14.6152 weeks$49.48
LBRX as reported
- Net income
- −$86M
Net income · trailing twelve months to Q2 2026
- Free cash flow
- −$83M
Free cash flow · trailing twelve months to Q2 2026
- EPS
- $0.14
EPS · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$86M | n/a | Q2 2026 |
| EPS | $0.14 | n/a | Q2 2026 |
| ROE | −13% | n/a | Q2 2026 |
| ROA | −12% | n/a | Q2 2026 |
| Free cash flow | −$83M | n/a | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
LB Pharmaceuticals Inc (LBRX) · Net incomeNet incomeLB Pharmaceuticals Inc (LBRX)
Biotechnology
The closest names by size in the same industry